Document is current
Any future updates will be listed below
-
Authors
Ghantous, Akram
Nusslé, Semira Gonseth
Nassar, Farah J.
Spitz, Natalia
Novoloaca, Alexei
Krali, Olga
Nickels, Eric
Cahais, Vincent
Cuenin, Cyrille
Roy, Ritu
Li, Shaobo
Caron, Maxime
Lam, Dilys
Fransquet, Peter Daniel
Casement, John
Strathdee, Gordon
Pearce, Mark S.
Hansen, Helen M.
Lee, Hwi-Ho
Lee, Yong Sun
de Smith, Adam J.
Sinnett, Daniel
Håberg, Siri Eldevik
McKay, Jill A.
Nordlund, Jessica
Magnus, Per
Dwyer, Terence
Saffery, Richard
Wiemels, Joseph Leo
Munthe-Kaas, Monica Cheng
Herceg, Zdenko
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 9 September 2024
First Online: 23 October 2024
Declarations
:
: The project was approved by the IARC Ethics Committee. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The MoBa cohort is currently regulated by the Norwegian Health Registry Act. The current study was approved by The Regional Committees for Medical and Health Research Ethics and the Norwegian Data Inspectorate (REK number 2011/2551b), and written informed consent was provided by both parents.For CCLS, written informed consent was obtained by the legal representative of all included participants. The California State and University of California IRBs have approved the study.For MEDC, newborn blood spot punches from children later diagnosed with ALL were obtained from archival Guthrie cards under a waiver of consent granted as part of the project ‘Epigenetic determinants of Childhood Cancer Incidence’ Human Research Ethics Committee Approval (HRE/16/RCHM/62).The UKCS study used samples from the Newcastle Biobank which holds approvals from the Newcastle and North Tyneside Research Ethics Committee 1 (17/NE/0361). Additional approvals specific to the use of neonatal blood spot samples and linkage of these samples to the Northern Region Young Persons' Malignant Disease Registry were obtained from the Health Research Authority Confidentiality Advisory Group (17CAG0177) and Newcastle and North Tyneside Research Ethics Committee 1 (17/NE/0334).For QcALL, informed consent was obtained from all participating individuals, and the Sainte-Justine UHC Institutional Review Board approved the research protocols.For NOPHO, the study was approved by the Regional Ethical Review Board in Uppsala, Sweden and was conducted according to the guidelines of the Declaration of Helsinki. The patients and/or their guardians provided informed consent.
: Not applicable.
: The authors declare no competing interests.
